Search for dissertations about: "preclinical study"
Showing result 1 - 5 of 155 swedish dissertations containing the words preclinical study.
-
1. Immunogene Therapy of Bladder Carcinoma : A Preclinical Study
Abstract : This thesis comprises studies on murine and human models of bladder carcinoma with the aim to develop novel immunogene therapies. On the basis of the results presented in this thesis, a clinical trial is underway. The potential of activating the immune system to combat cancer has long intrigued immunologists. READ MORE
-
2. Tumour Targeting Using Radiolabelled EGF Conjugates : Preclinical Studies
Abstract : Tumour targeted radiotherapy is an appealing approach for treatment of disseminated tumour cells. A targeting agent that specifically binds to a structure on tumour cells is then used to transport therapeutically relevant radionuclides. The epidermal growth factor receptor, EGFR, is overexpressed on tumour cells in several malignancies, e.g. READ MORE
-
3. Preclinical tumor-immune modeling : For the identification of immunomodulatory drugs
Abstract : For a long time, the field of cancer research was dominated by a tumor cell-centric view. That, however, changed once it became recognized that medical cancer treatment is largely influenced by the combined effect exerted on both cancer and immune cells. READ MORE
-
4. Brain glycine receptors as a common target for alcohol and the relapse-preventing drug acamprosate - a preclinical study
Abstract : Alcohol abuse and dependence make up the most prevalent categories of substance use disorders in the world. Converging evidence from the current research group has identified two receptor populations, the glycine (GlyRs) and nicotinic acetylcholine receptors (nAChRs) in the mesolimbic dopamine system, as two potentially important targets for the development of new medication to treat alcohol dependence. READ MORE
-
5. Cancer Immunotherapy : A Preclinical Study of Urinary Bladder Cancer
Abstract : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. READ MORE